Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush

2026-04-01 09:48:43 ET

Oric Pharmaceuticals ( NASDAQ:ORIC – Get Free Report ) had its target price dropped by Wedbush from $20.00 to $17.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective indicates a potential upside of 34.18% from the stock’s previous close.

A number of other brokerages have also weighed in on ORIC. Citigroup upped their target price on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Wells Fargo & Company raised their price objective on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Oric Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $19.90.

View Our Latest Stock Report on Oric Pharmaceuticals

Oric Pharmaceuticals Trading Up 3.9%

Shares of NASDAQ ORIC opened at $12.67 on Wednesday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -8.34 and a beta of 1.28. The firm’s 50-day moving average price is $11.72 and its 200-day moving average price is $11.34. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.93.

Oric Pharmaceuticals ( NASDAQ:ORIC – Get Free Report ) last issued its earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. Equities research analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Transactions at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 52,000 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares in the company, valued at $920,679.48. This represents a 43.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . 5.55% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORIC. Vanguard Group Inc. lifted its position in shares of Oric Pharmaceuticals by 48.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after buying an additional 1,525,445 shares in the last quarter. Alkeon Capital Management LLC lifted its holdings in Oric Pharmaceuticals by 12.5% during the second quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after acquiring an additional 500,000 shares during the period. State Street Corp lifted its holdings in Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after acquiring an additional 1,854,458 shares during the period. Orbimed Advisors LLC boosted its position in Oric Pharmaceuticals by 305.0% in the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after purchasing an additional 2,742,475 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Oric Pharmaceuticals by 14.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock valued at $26,955,000 after purchasing an additional 423,795 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

( Get Free Report )

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

Read More

• Five stocks we like better than Oric Pharmaceuticals